Evaluation of Erythroferrone as a New Biomarker of Erythropoesis Stimulating Agents

Inclusion Criteria: * Man between 18 and 49 years old * Beneficiary of a social protection scheme * Able to sign informed consent Exclusion Criteria: * Hematocrite\>50% or Hemoglobin\> 17d/dl or Ferritin\<30 ug/l * Hypersensitivity to the active substance or to any of the excipients ofEPREX * Erythroblastopenia already reported following treatment with erythropoietin * Uncontrolled hypertension * Any medication taken as part of a chronic treatment * Absence of stable or evolutionary pathology without treatment * History of convulsion or epilepsy * History of thrombotic vascular events * Large blood loss due to an accident, pathological condition or other similar situation. * Donation of blood or blood transfusion within three months prior to inclusion in the protocol.